TheraCryf PLC
Company Profile
Business description
TheraCryf PLC is a biotechnology company developing new medicines for addiction and other neuropsychiatric disorders, areas of unmet medical need within central nervous system (CNS) disorders. The Group's main programme is a novel, benchmark orexin-1 receptor antagonist being developed as a potential treatment for addiction, including binge eating, alcohol, and other substance use disorders. It also has a dopamine transporter (DAT) modulator programme addressing fatigue of brain origin, including fatigue associated with multiple sclerosis, chemotherapy, and narcolepsy. The Group also has an oncology programme in glioblastoma with SFX-01. It operates a capital-light, virtual development model advancing programmes to early clinical or proof-of-concept stage before partnering.
Contact
Congleton Road
Alderley Park
Nether AlderleyCheshireSK10 4TG
GBRT: +44 1625315090
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
9
Stocks News & Analysis
stocks
The 10 best US companies to invest in now
stocks
Surge in combat drones drives upgrade for ASX share
stocks
Meta: Meta launches enterprise offering to open up another way to monetize AI investments
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,831.80 | 37.40 | 0.43% |
| CAC 40 | 7,835.31 | 129.20 | -1.62% |
| DAX 40 | 24,939.35 | 259.84 | -1.03% |
| Dow JONES (US) | 50,926.56 | 20.51 | 0.04% |
| FTSE 100 | 10,428.27 | 177.73 | -1.68% |
| HKSE | 23,969.30 | 643.97 | -2.62% |
| NASDAQ | 26,871.60 | 10.53 | 0.04% |
| Nikkei 225 | 68,326.72 | 630.00 | -0.91% |
| NZX 50 Index | 13,664.70 | 145.81 | -1.06% |
| S&P 500 | 7,666.45 | 14.91 | 0.19% |
| S&P/ASX 200 | 8,656.70 | 42.30 | 0.49% |
| SSE Composite Index | 3,842.19 | 11.74 | 0.31% |